Advice
in the absence of a submission from the holder of the marketing authorisation
ramucirumab (Cyramza®) is not recommended for use within NHS Scotland.
Indication under review: in combination with docetaxel for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice49KB (PDF)
Medicine details
- Medicine name:
- ramucirumab (Cyramza)
- SMC ID:
- 1165/16
- Indication:
- in combination with docetaxel for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.
- Pharmaceutical company
- Lilly UK
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 13 June 2016